



Muiden IPR:n hyödyntäminen – in-licensing

Heidi Adler

13.12.2022

Orion produces and exports active pharmaceutical ingredients and finished products to the global market

ORION has 6 manufacturing plants in **FINLAND**, sales offices in 31 countries

ORION exports its own products to more than 100 countries worldwide

METHOTREXATE
- global market share more than 30%

DAROLUTAMIDE
1 in 7 cancer patients has prostate cancer. 1.2 million new patients per year

ENTACAPONE
- in more than 50% of the world's Parkinson's drugs



Orion today

Orion is developing, manufacturing and marketing human and veterinary pharmaceuticals and active pharmaceutical ingredients



Net sales **1,041** MEUR



Operating profit **243** MEUR



Personnel **3,355**



R&D investments **118** MEUR




6 production sites in Finland



Own sales unit in **26** European and **5** Asia-Pacific countries


Established in **1917**

Sales by business



- Proprietary Products
- Specialty Products
- Animal Health
- Fermion & CM*



Sales by market area




- Finland
- Scandinavia
- Other Europe
- North America
- ROW

*) Contract manufacturing

2025 Growth target - In-licensing as a growth driver



Key clinical development pipeline



Oncology

Pain / neurology


¹ In collaboration with Bayer

² In collaboration with MSD

Updates vs. Q2 2022:

- Development of Easyhaler® tiotropium terminated
- ODM-105 Phase I ready
- ODM-111 entered Phase I

CAR T-soluterapia-tutkimushanke yhteistyössä Suomen Punaisen Ristin Veripalvelun kanssa





Kiitos.....

13 December 2022 Heidi Adler / Orion Corporation

